Incorporation of a new radioactive compound, 4+Sn-117m DTPA, into normal and burred rat femurs.
The physical characteristics of a new tin radiopharmaceutical, 4+Sn-117m diethylenetriamine-pentaacetic acid (DTPA), may make this compound appropriate for orthopedic therapeutic application. The physical and biologic half-lives of this tracer are 14 and 7.8 days, respectively. The decay scheme consists of short-range tissue destroying beta, conversion, and Auger electrons, and a 159-keV gamma ray. Significantly, this compound has a high degree of affinity for newly calcified bone at the site of experimental burr holes in contrast to the adjacent bone marrow. Radioactive skeletal retention was one-half of whole body retention.
L C
LC
Hurst
M A
MA
Badalamente
Z H
ZH
Oster
H L
HL
Atkins
D
D
Weissberg
D000818:Animals; D001345:Autoradiography; D001842:Bone and Bones / Q000378:metabolism; D005269:Femur / Q000000981:diagnostic imaging*; D006207:Half-Life; D004369:Pentetic Acid / Q000378:metabolism; D011877:Radionuclide Imaging; D051381:Rats; D011919:Rats, Inbred Strains; D013667:Technetium / Q000378:metabolism; D016284:Technetium Tc 99m Pentetate / Q000031:analogs & derivatives*; D014945:Wound Healing
C034230:technetium Tc 99m-Sn-DTPA; D013667:Technetium; D004369:Pentetic Acid; D016284:Technetium Tc 99m Pentetate